Feedback / Questions
VK2735 Oral - Viking Therap
VK2735 SC - Viking Therap
https://www.prnewswire.com/news-releases/viking-therapeutics-announces-initiation-of-phase-3-obesity-clinical-program-with-glp-1gip-agonist-vk2735-302490496.html
Jun 25, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next